US approves first drug treatment for sleep apnea | The Peninsula Qatar
US FDA approves Zepbound, a weight-loss drug by Eli Lilly, for treating moderate to severe obstructive sleep apnea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.
Highlighted Terms
Related News
US approves first drug treatment for sleep apnea | The Peninsula Qatar
US FDA approves Zepbound, a weight-loss drug by Eli Lilly, for treating moderate to severe obstructive sleep apnea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.